The Next Wave of Genetic Medicines for Rett
On June 23, a record number of viewers tuned into our live webinar to receive an update on the rapidly evolving landscape of genetic medicines for Rett syndrome.
On June 23, a record number of viewers tuned into our live webinar, The Next Wave of Genetic Medicines for Rett Syndrome, to receive an update on the rapidly evolving landscape of genetic medicines for Rett syndrome. Newomer biotech companies to the Rett space were introduced, updates to genetic medicine programs were provided along with timelines for this next wave of clinical trials.
Founder and CEO, Monica Coenraads, was joined by Chief Medical Officer, Jenny Laforet, MD, PhD; Chief Technology Officer, Bob Deans, PhD; Director of Research, John Sinnamon, PhD; and Chief Development Officer, Tim Freeman, with an extended Q&A to close.
